{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:11:52Z","timestamp":1789593112102,"version":"build-2803163510"},"reference-count":261,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001602","name":"Taighde \u00c9ireann - Research Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.blre.2025.101360","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T23:53:58Z","timestamp":1766447638000},"page":"101360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Metabolic alterations in multiple myeloma and extramedullary disease- a novel niche of therapeutic targets"],"prefix":"10.1016","volume":"76","author":[{"given":"Ellen","family":"Purcell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"O\u2019Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Bazou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.blre.2025.101360_bb0005","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma: medical progress","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.blre.2025.101360_bb0010","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.blre.2025.101360_bb0015","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2025.101360_bb0020","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.blre.2025.101360_bb0025","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2025.101360_bb0030","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2025.101360_bb0035","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/asheducation-2013.1.478","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies","volume":"2013","author":"Landgren","year":"2013","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2025.101360_bb0040","article-title":"Single-cell sequencing reveals the mechanisms of multiple myeloma progression: clarity or confusion?","volume":"1-18","author":"Xiang","year":"2025","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2025.101360_bb0045","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"Van de Donk","year":"2021","journal-title":"Lancet Lond Engl"},{"issue":"4","key":"10.1016\/j.blre.2025.101360_bb0050","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.beha.2007.09.003","article-title":"Bortezomib in multiple myeloma","volume":"20","author":"Mateos","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"10.1016\/j.blre.2025.101360_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101143","article-title":"Monoclonal antibodies in multiple myeloma: current and emerging targets and mechanisms of action","volume":"33","author":"Wudhikarn","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.blre.2025.101360_bb0060","first-page":"5759","article-title":"Immunomodulatory agents for multiple myeloma","author":"Mina\u0159\u00edk","year":"2022","journal-title":"MDPI"},{"issue":"1","key":"10.1016\/j.blre.2025.101360_bb0065","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3324\/haematol.2019.219295","article-title":"A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome","volume":"105","author":"Beksac","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101360_bb0070","article-title":"Extramedullary disease in multiple myeloma at diagnosis and over the course of the disease","volume":"1-10","author":"Guliyev","year":"2025","journal-title":"Int J Hematol"},{"issue":"28","key":"10.1016\/j.blre.2025.101360_bb0075","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","article-title":"Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach","volume":"29","author":"Blad\u00e9","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2025.101360_bb0080","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3109\/10428194.2012.740562","article-title":"Extramedullary multiple myeloma","volume":"54","author":"Weinstock","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.blre.2025.101360_bb0085","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients","volume":"21","author":"Varettoni","year":"2010","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb0090","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.blre.2025.101360_bb0095","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41408-021-00527-y","article-title":"Extramedullary disease in multiple myeloma","volume":"11","author":"Bansal","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb0100","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","article-title":"The hallmarks of cancer metabolism: Still emerging","volume":"34","author":"Pavlova","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.blre.2025.101360_bb0105","series-title":"Biochemistry (Loose-Leaf)","author":"Berg","year":"2007"},{"issue":"8","key":"10.1016\/j.blre.2025.101360_bb0110","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.4049\/jimmunol.1302062","article-title":"Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells","volume":"192","author":"Caro-Maldonado","year":"2014","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.blre.2025.101360_bb0115","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1182\/blood-2005-12-4788","article-title":"Antigen receptor\u2013mediated changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth","volume":"107","author":"Doughty","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2025.101360_bb0120","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3390\/genes14040933","article-title":"The hexosamine biosynthesis pathway: regulation and function","volume":"14","author":"Paneque","year":"2023","journal-title":"Genes"},{"issue":"5","key":"10.1016\/j.blre.2025.101360_bb0125","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.it.2017.02.004","article-title":"The immunoregulatory roles of antibody glycosylation","volume":"38","author":"Jennewein","year":"2017","journal-title":"Trends Immunol"},{"key":"10.1016\/j.blre.2025.101360_bb0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10863-012-9412-9","article-title":"Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate","volume":"44","author":"Nakano","year":"2012","journal-title":"J Bioenerg Biomembr"},{"key":"10.1016\/j.blre.2025.101360_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0392-4","article-title":"NEK2 promotes aerobic glycolysis in multiple myeloma through regulating splicing of pyruvate kinase","volume":"10","author":"Gu","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.blre.2025.101360_bb0140","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1093\/nar\/gkv047","article-title":"Regulation of mammalian nucleotide metabolism and biosynthesis","volume":"43","author":"Lane","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"34","key":"10.1016\/j.blre.2025.101360_bb0145","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1038\/sj.onc.1209595","article-title":"Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt","volume":"25","author":"Ra","year":"2006","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.blre.2025.101360_bb0150","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.canlet.2014.01.031","article-title":"PKM2 contributes to cancer metabolism","volume":"356","author":"Wong","year":"2015","journal-title":"Cancer Lett"},{"issue":"263","key":"10.1016\/j.blre.2025.101360_bb0155","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2003925","article-title":"Allosteric regulation of PKM2 allows cellular adaptation to different physiological states","volume":"6","author":"Gui","year":"2013","journal-title":"Sci Signal"},{"issue":"7184","key":"10.1016\/j.blre.2025.101360_bb0160","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature06734","article-title":"The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth","volume":"452","author":"Christofk","year":"2008","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.blre.2025.101360_bb0165","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/leu.2016.389","article-title":"PKM2 and other key regulators of Warburg effect positively correlate with CD147 (EMMPRIN) gene expression and predict survival in multiple myeloma","volume":"31","author":"Panchabhai","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.blre.2025.101360_bb0170","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.leukres.2015.09.019","article-title":"Pyruvate kinase isoform M2 (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance","volume":"39","author":"He","year":"2015","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.blre.2025.101360_bb0175","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/2045-3701-4-20","article-title":"Activation of Akt protects cancer cells from growth inhibition induced by PKM2 knockdown","volume":"4","author":"Qin","year":"2014","journal-title":"Cell & Biosci"},{"issue":"15","key":"10.1016\/j.blre.2025.101360_bb0180","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1182\/bloodadvances.2025016619","article-title":"Extramedullary myeloma is genomically complex and characterized by near-universal MAPK pathway alterations","volume":"9","author":"Zanwar","year":"2025","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.blre.2025.101360_bb0185","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.molcel.2012.01.001","article-title":"Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase","volume":"45","author":"Gao","year":"2012","journal-title":"Mol Cell"},{"key":"10.1016\/j.blre.2025.101360_bb0190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12943-015-0490-2","article-title":"PKM2 promotes tumor angiogenesis by regulating HIF-1\u03b1 through NF-\u03baB activation","volume":"15","author":"Azoitei","year":"2016","journal-title":"Mol Cancer"},{"issue":"7375","key":"10.1016\/j.blre.2025.101360_bb0195","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature10598","article-title":"Nuclear PKM2 regulates \u03b2-catenin transactivation upon EGFR activation","volume":"480","author":"Yang","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.blre.2025.101360_bb0200","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12929-025-01170-6","article-title":"Nuclear PKM2: a signal receiver, a gene programmer, and a metabolic modulator","volume":"32","author":"Chen","year":"2025","journal-title":"J Biomed Sci"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb0205","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.yexmp.2010.08.006","article-title":"Cancer metabolism: the Warburg effect today","volume":"89","author":"Ferreira","year":"2010","journal-title":"Exp Mol Pathol"},{"issue":"9","key":"10.1016\/j.blre.2025.101360_bb0210","article-title":"The Warburg effect in multiple myeloma and its microenvironment","volume":"5","author":"K\u00fchnel","year":"2017","journal-title":"Med Res Arch"},{"issue":"7","key":"10.1016\/j.blre.2025.101360_bb0215","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/09553002.2019.1589653","article-title":"The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression","volume":"95","author":"Vaupel","year":"2019","journal-title":"Int J Radiat Biol"},{"issue":"19","key":"10.1016\/j.blre.2025.101360_bb0220","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.4161\/cc.26193","article-title":"CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells","volume":"12","author":"Walters","year":"2013","journal-title":"Cell Cycle"},{"issue":"21","key":"10.1016\/j.blre.2025.101360_bb0225","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood.V122.21.3109.3109","article-title":"Lactate is a crucial energy source for multiple myeloma (MM) cells in bone marrow microenvironment","volume":"122","author":"Fujiwara","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101360_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-015-0008-z","article-title":"Lactate, a putative survival factor for myeloma cells, is incorporated by myeloma cells through monocarboxylate transporters 1","volume":"4","author":"Fujiwara","year":"2015","journal-title":"Exp Hematol Oncol"},{"issue":"52","key":"10.1016\/j.blre.2025.101360_bb0235","doi-asserted-by":"crossref","first-page":"20135","DOI":"10.1074\/jbc.RA119.009093","article-title":"Monocarboxylate transporter 4 (MCT4) is a high affinity transporter capable of exporting lactate in high-lactate microenvironments","volume":"294","author":"Contreras-Baeza","year":"2019","journal-title":"J Biol Chem"},{"issue":"23","key":"10.1016\/j.blre.2025.101360_bb0240","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.4161\/cc.8.23.10238","article-title":"The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma","volume":"8","author":"Pavlides","year":"2009","journal-title":"Cell Cycle"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb0245","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000375435","article-title":"Warburg effect or reverse Warburg effect? A review of cancer metabolism","volume":"38","author":"Xu","year":"2015","journal-title":"Oncol Res Treat"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb0250","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cell.2005.02.034","article-title":"Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1\/CXCL12 secretion","volume":"121","author":"Orimo","year":"2005","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.blre.2025.101360_bb0255","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.4161\/cc.9.12.11989","article-title":"Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling","volume":"9","author":"Migneco","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.blre.2025.101360_bb0260","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10555-011-9340-x","article-title":"Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression","volume":"31","author":"Cirri","year":"2012","journal-title":"Cancer Metastasis Rev"},{"issue":"5930","key":"10.1016\/j.blre.2025.101360_bb0265","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.blre.2025.101360_bb0270","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1158\/1078-0432.CCR-19-0694","article-title":"Alterations in the transcriptional programs of myeloma cells and the microenvironment during extramedullary progression affect proliferation and immune evasion","volume":"26","author":"Ryu","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.blre.2025.101360_bb0275","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1158\/1078-0432.CCR-14-1088","article-title":"Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin","volume":"21","author":"Dalva-Aydemir","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"47","key":"10.1016\/j.blre.2025.101360_bb0280","doi-asserted-by":"crossref","first-page":"36395","DOI":"10.1074\/jbc.M110.176321","article-title":"Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice","volume":"285","author":"Vyas","year":"2010","journal-title":"J Biol Chem"},{"issue":"23","key":"10.1016\/j.blre.2025.101360_bb0285","first-page":"6763","article-title":"The phosphatidylinositol 3-kinase\/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses","volume":"60","author":"Tu","year":"2000","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.blre.2025.101360_bb0290","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K\u2013AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.blre.2025.101360_bb0295","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"14","key":"10.1016\/j.blre.2025.101360_bb0300","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1182\/blood-2014-03-559963","article-title":"The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma","volume":"124","author":"Spencer","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb0305","first-page":"193","article-title":"Innovative agents in multiple myeloma","volume":"5","author":"Faiman","year":"2014","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.blre.2025.101360_bb0310","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.canlet.2018.06.020","article-title":"Pharmacologic inhibition of AKT leads to cell death in relapsed multiple myeloma","volume":"432","author":"Song","year":"2018","journal-title":"Cancer Lett"},{"issue":"21","key":"10.1016\/j.blre.2025.101360_bb0315","first-page":"283","article-title":"Novel AKT inhibitor afuresertib in combination with bortezomib and dexamethasone demonstrates favorable safety profile and significant clinical activity in patients with relapsed\/refractory multiple myeloma","volume":"122","author":"Voorhees","year":"2013","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2025.101360_bb0320","doi-asserted-by":"crossref","first-page":"4526","DOI":"10.1182\/blood.V128.22.4526.4526","volume":"128","author":"Trudel","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2025.101360_bb0325","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/bloodadvances.2022007383","article-title":"AKT supports the metabolic fitness of multiple myeloma cells by restricting FOXO activity","volume":"7","author":"Bloedjes","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.blre.2025.101360_bb0330","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.2174\/138945011796150244","article-title":"FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy","volume":"12","author":"Wilson","year":"2011","journal-title":"Curr Drug Targets"},{"issue":"32","key":"10.1016\/j.blre.2025.101360_bb0335","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1038\/s41388-022-02398-4","article-title":"FOXM1 regulates glycolysis and energy production in multiple myeloma","volume":"41","author":"Cheng","year":"2022","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.blre.2025.101360_bb0340","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/jcp.20339","article-title":"Molecular mechanisms of glutamine action","volume":"204","author":"Curi","year":"2005","journal-title":"J Cell Physiol"},{"issue":"7","key":"10.1016\/j.blre.2025.101360_bb0345","doi-asserted-by":"crossref","DOI":"10.3390\/metabo13070793","article-title":"Red blood cell metabolism in vivo and in vitro","volume":"13","author":"D\u2019Alessandro","year":"2023","journal-title":"Metabolites"},{"issue":"6","key":"10.1016\/j.blre.2025.101360_bb0350","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/00000658-199312000-00004","article-title":"Glutamine and cancer","volume":"218","author":"Souba","year":"1993","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.blre.2025.101360_bb0355","doi-asserted-by":"crossref","first-page":"578","DOI":"10.2741\/3707","article-title":"Regulation of protein metabolism by glutamine: implications for nutrition and health","volume":"16","author":"Xi","year":"2011","journal-title":"Front Biosci"},{"issue":"5","key":"10.1016\/j.blre.2025.101360_bb0360","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-01-690743","article-title":"Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target","volume":"128","author":"Bolzoni","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101360_bb0365","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1182\/blood-2023-186637","article-title":"Glutamine addiction of multiple myeloma cells reprograms mesenchymal stromal cell enzymes and transporters towards a pro-tumor phenotype","volume":"142","author":"Chiu","year":"2023","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2025.101360_bb0370","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.2019001034","article-title":"Amino acid metabolism in hematologic malignancies and the era of targeted therapy","volume":"134","author":"Tabe","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2025.101360_bb0375","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1111\/cas.12529","article-title":"Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma","volume":"105","author":"Isoda","year":"2014","journal-title":"Cancer Sci"},{"issue":"11","key":"10.1016\/j.blre.2025.101360_bb0380","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.3390\/nu10111564","article-title":"Glutamine: metabolism and immune function, supplementation and clinical translation","volume":"10","author":"Cruzat","year":"2018","journal-title":"Nutrients"},{"issue":"7443","key":"10.1016\/j.blre.2025.101360_bb0385","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature12040","article-title":"Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway","volume":"496","author":"Son","year":"2013","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb0390","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1021\/acs.biochem.4c00763","article-title":"Glutamine Synthetase: Diverse Regulation and Functions of an Ancient Enzyme","volume":"64","author":"Tecson","year":"2025","journal-title":"Biochemistry"},{"issue":"11","key":"10.1016\/j.blre.2025.101360_bb0395","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113267","article-title":"Myeloma cells deplete bone marrow glutamine and inhibit osteoblast differentiation limiting asparagine availability","volume":"12","author":"Chiu","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"Suppl. 3","key":"10.1016\/j.blre.2025.101360_bb0400","doi-asserted-by":"crossref","first-page":"S578","DOI":"10.21037\/tcr.2017.05.05","article-title":"Branched chain amino acid metabolism and cancer: the importance of keeping things in context","volume":"6","author":"Selwan","year":"2017","journal-title":"Transl Cancer Res"},{"issue":"7","key":"10.1016\/j.blre.2025.101360_bb0405","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.3390\/ijms23074022","article-title":"The critical role of the branched chain amino acids (BCAAs) catabolism-regulating enzymes, branched-chain aminotransferase (BCAT) and branched-chain \u03b1-keto acid dehydrogenase (BCKD), in human pathophysiology","volume":"23","author":"Dimou","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6056","key":"10.1016\/j.blre.2025.101360_bb0410","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1126\/science.1207056","article-title":"mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H+-ATPase","volume":"334","author":"Zoncu","year":"2011","journal-title":"Science"},{"issue":"6268","key":"10.1016\/j.blre.2025.101360_bb0415","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.aab2674","article-title":"Sestrin2 is a leucine sensor for the mTORC1 pathway","volume":"351","author":"Wolfson","year":"2016","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.blre.2025.101360_bb0420","doi-asserted-by":"crossref","first-page":"E1329","DOI":"10.1152\/ajpendo.00525.2011","article-title":"Leucine and mTORC1: a complex relationship","volume":"302","author":"Dodd","year":"2012","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"14","key":"10.1016\/j.blre.2025.101360_bb0425","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1182\/bloodadvances.2022008242","article-title":"Human acute leukemia uses branched-chain amino acid catabolism to maintain stemness through regulating PRC2 function","volume":"7","author":"Yoshikane","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.blre.2025.101360_bb0430","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","article-title":"EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast","volume":"24","author":"Bachmann","year":"2006","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.blre.2025.101360_bb0435","doi-asserted-by":"crossref","first-page":"8570","DOI":"10.1158\/1078-0432.CCR-05-1047","article-title":"Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder","volume":"11","author":"Raman","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.blre.2025.101360_bb0440","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/carcin\/bgq150","article-title":"EZH2 supports ovarian carcinoma cell invasion and\/or metastasis via regulation of TGF-\u03b21 and is a predictor of outcome in ovarian carcinoma patients","volume":"31","author":"Rao","year":"2010","journal-title":"Carcinogenesis"},{"issue":"2","key":"10.1016\/j.blre.2025.101360_bb0445","first-page":"345","article-title":"Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus","volume":"38","author":"Yamada","year":"2011","journal-title":"Int J Oncol"},{"issue":"1","key":"10.1016\/j.blre.2025.101360_bb0450","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13148-018-0554-4","article-title":"PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs","volume":"10","author":"Herviou","year":"2018","journal-title":"Clin Epigenetics"},{"issue":"2","key":"10.1016\/j.blre.2025.101360_bb0455","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.2651","article-title":"Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia","volume":"18","author":"Ntziachristos","year":"2012","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.blre.2025.101360_bb0460","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1172\/JCI80325","article-title":"Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma","volume":"125","author":"Kikuchi","year":"2015","journal-title":"J Clin Invest"},{"issue":"26","key":"10.1016\/j.blre.2025.101360_bb0465","doi-asserted-by":"crossref","first-page":"E3735","DOI":"10.1073\/pnas.1602079113","article-title":"HIFI-\u03b1 activation underlies a functional switch in the paradoxical role of Ezh2\/PRC2 in breast cancer","volume":"113","author":"Mahara","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.blre.2025.101360_bb0470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-018-0148-5","article-title":"EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies","volume":"6","author":"Tremblay-LeMay","year":"2018","journal-title":"Biomark Res"},{"issue":"6","key":"10.1016\/j.blre.2025.101360_bb0475","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/s41375-024-02206-w","article-title":"Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors","volume":"38","author":"Jelinek","year":"2024","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.blre.2025.101360_bb0480","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/s41419-021-04212-7","article-title":"Tumor-suppressive function of EZH2 is through inhibiting glutaminase","volume":"12","author":"Liu","year":"2021","journal-title":"Cell Death Dis"},{"issue":"4","key":"10.1016\/j.blre.2025.101360_bb0485","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1113\/JP275075","article-title":"Restoration of metabolic health by decreased consumption of branched-chain amino acids","volume":"596","author":"Cummings","year":"2018","journal-title":"J Physiol"},{"issue":"6","key":"10.1016\/j.blre.2025.101360_bb0490","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.metabol.2014.03.006","article-title":"Effects of individual branched-chain amino acids deprivation on insulin sensitivity and glucose metabolism in mice","volume":"63","author":"Xiao","year":"2014","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb0495","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/bjc.1998.77","article-title":"Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: updated results of the MM87 prospective randomized protocol","volume":"77","author":"Riccardi","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.blre.2025.101360_bb0500","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ceb.2017.02.012","article-title":"mTORC1 signaling and the metabolic control of cell growth","volume":"45","author":"Ben-Sahra","year":"2017","journal-title":"Curr Opin Cell Biol"},{"issue":"15","key":"10.1016\/j.blre.2025.101360_bb0505","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15153764","article-title":"Proteomic and metabolomic analysis of bone marrow and plasma from patients with extramedullary multiple myeloma identifies distinct protein and metabolite signatures","volume":"15","author":"Dunphy","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.blre.2025.101360_bb0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep14752","article-title":"Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma","volume":"5","author":"Nath","year":"2015","journal-title":"Sci Rep"},{"issue":"58","key":"10.1016\/j.blre.2025.101360_bb0515","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.22131","article-title":"CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma","volume":"8","author":"Alaterre","year":"2017","journal-title":"Oncotarget"},{"issue":"72","key":"10.1016\/j.blre.2025.101360_bb0520","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.272re3","article-title":"CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior","volume":"2","author":"Silverstein","year":"2009","journal-title":"Sci Signal"},{"issue":"41","key":"10.1016\/j.blre.2025.101360_bb0525","doi-asserted-by":"crossref","first-page":"31002","DOI":"10.1074\/jbc.M602794200","article-title":"Membrane sorting of toll-like receptor (TLR)-2\/6 and TLR2\/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting","volume":"281","author":"Triantafilou","year":"2006","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.blre.2025.101360_bb0530","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.devcel.2013.01.007","article-title":"Multimolecular signaling complexes enable Syk-mediated signaling of CD36 internalization","volume":"24","author":"Heit","year":"2013","journal-title":"Dev Cell"},{"issue":"12","key":"10.1016\/j.blre.2025.101360_bb0535","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029092","article-title":"CD9 tetraspanin interacts with CD36 on the surface of macrophages: a possible regulatory influence on uptake of oxidized low density lipoprotein","volume":"6","author":"Huang","year":"2011","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.blre.2025.101360_bb0540","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1182\/blood.2021013832","article-title":"Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins","volume":"139","author":"Panaroni","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb0545","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41574-018-0126-x","article-title":"The obese adipose tissue microenvironment in cancer development and progression","volume":"15","author":"Quail","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.blre.2025.101360_bb0550","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1118691","article-title":"Obesity and myeloma: clinical and mechanistic contributions to disease progression","volume":"14","author":"Marques-Mourlet","year":"2023","journal-title":"Front Endocrinol"},{"issue":"11","key":"10.1016\/j.blre.2025.101360_bb0555","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1016\/j.ajpath.2016.07.012","article-title":"Adipocyte-lineage cells support growth and dissemination of multiple myeloma in bone","volume":"186","author":"Trotter","year":"2016","journal-title":"Am J Pathol"},{"key":"10.1016\/j.blre.2025.101360_bb0560","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.81184","article-title":"Targeting the fatty acid binding proteins disrupts multiple myeloma cell cycle progression and MYC signaling","volume":"12","author":"Farrell","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.blre.2025.101360_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.jprot.2020.104015","article-title":"Saliva-omics in plasma cell disorders-Proof of concept and potential as a non-invasive tool for monitoring disease burden","volume":"231","author":"Tierney","year":"2021","journal-title":"J Proteome"},{"issue":"6","key":"10.1016\/j.blre.2025.101360_bb0570","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ajh.25778","article-title":"Statin use is associated with improved survival in multiple myeloma: a Swedish population-based study of 4315 patients","volume":"95","author":"Br\u00e5nvall","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101360_bb0575","series-title":"Statin Medications","author":"Sizar","year":"2024"},{"issue":"4","key":"10.1016\/j.blre.2025.101360_bb0580","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41580-019-0190-7","article-title":"Mechanisms and regulation of cholesterol homeostasis","volume":"21","author":"Luo","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb0585","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2362.1994.tb00984.x","article-title":"Enhanced cellular metabolism of very low density lipoprotein by simvastatin. A novel mechanism of action of HMG-CoA reductase inhibitors","volume":"24","author":"Sehayek","year":"1994","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.blre.2025.101360_bb0590","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00277-011-1246-8","article-title":"Low-density lipoprotein cholesterol suppresses apoptosis in human multiple myeloma cells","volume":"91","author":"Tirado-V\u00e9lez","year":"2012","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.blre.2025.101360_bb0595","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s12944-024-02289-5","article-title":"Lipid levels and multiple myeloma risk: insights from meta-analysis and mendelian randomization","volume":"23","author":"Zhu","year":"2024","journal-title":"Lipids Health Dis"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb0600","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.bbrc.2016.08.061","article-title":"Hepatic Elovl6 gene expression is regulated by the synergistic action of ChREBP and SREBP-1c","volume":"478","author":"Bae","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.blre.2025.101360_bb0605","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.bbrc.2008.01.075","article-title":"Mouse Elovl-6 promoter is an SREBP target","volume":"368","author":"Kumadaki","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"10.1016\/j.blre.2025.101360_bb0610","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1182\/bloodadvances.2020002578","article-title":"The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma","volume":"5","author":"Lipchick","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2025.101360_bb0615","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2049-3002-1-3","article-title":"Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth","volume":"1","author":"Griffiths","year":"2013","journal-title":"Cancer Metab"},{"key":"10.1016\/j.blre.2025.101360_bb0620","series-title":"Vitamin D: Production, Metabolism and Mechanisms of Action","author":"Bikle","year":"2015"},{"key":"10.1016\/j.blre.2025.101360_bb0625","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fphys.2014.00137","article-title":"Vitamin D and gene networks in human osteoblasts","volume":"5","author":"van de Peppel","year":"2014","journal-title":"Front Physiol"},{"issue":"11","key":"10.1016\/j.blre.2025.101360_bb0630","first-page":"6281","article-title":"Prevalence of vitamin D deficiency in patients with bone metastases and multiple myeloma","volume":"35","author":"Maier","year":"2015","journal-title":"Anticancer Res"},{"issue":"7","key":"10.1016\/j.blre.2025.101360_bb0635","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ajh.21412","article-title":"Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma","volume":"84","author":"Ng","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101360_bb0640","first-page":"1249","article-title":"A retrospective analysis of the prevalence and clinical outcomes of vitamin D deficiency in myeloma patients in tropical Australia","volume":"28","author":"Nath","year":"2020","journal-title":"Support Care Cancer"},{"issue":"11","key":"10.1016\/j.blre.2025.101360_bb0645","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.25850","article-title":"Effect of vitamin D3 supplements on development of advanced cancer: a secondary analysis of the VITAL randomized clinical trial","volume":"3","author":"Chandler","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.blre.2025.101360_bb0650","first-page":"271","article-title":"High prevalence of peripheral neuropathy in multiple myeloma patients and the impact of vitamin D levels, a cross-sectional study","volume":"30","author":"Oortgiesen","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.blre.2025.101360_bb0655","first-page":"3105","article-title":"Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and\/or thalidomide and is associated with severe neuropathy","volume":"24","author":"Wang","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.blre.2025.101360_bb0660","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1157969","article-title":"Vitamin D deficiency linked to abnormal bone and lipid metabolism predicts high-risk multiple myeloma with poorer prognosis","volume":"14","author":"Bao","year":"2023","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.blre.2025.101360_bb0665","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1210\/jc.2009-1518","article-title":"Lactation and bone turnover: a conundrum of marked bone loss in the setting of coupled bone turnover","volume":"95","author":"Carneiro","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.blre.2025.101360_bb0670","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1182\/bloodadvances.2023010843","article-title":"Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population","volume":"8","author":"Lee","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.blre.2025.101360_bb0675","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41375-021-01443-7","article-title":"A comprehensive review of the impact of obesity on plasma cell disorders","volume":"36","author":"Parikh","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101360_bb0680","doi-asserted-by":"crossref","first-page":"20","DOI":"10.18632\/oncotarget.28548","article-title":"Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma","volume":"15","author":"El-Masri","year":"2024","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.blre.2025.101360_bb0685","doi-asserted-by":"crossref","first-page":"5872","DOI":"10.1182\/blood-2011-01-330407","article-title":"Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease","volume":"118","author":"Fowler","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2025.101360_bb0690","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1530\/ERC-15-0029","article-title":"Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium","volume":"22","author":"R\u00edos","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"10.1016\/j.blre.2025.101360_bb0695","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.3390\/cancers12113226","article-title":"The acidic microenvironment: Is it a phenotype of all cancers? a focus on multiple myeloma and some analogies with diabetes mellitus","volume":"12","author":"Fais","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.blre.2025.101360_bb0700","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000505992","article-title":"The association between metabolic syndrome and multiple myeloma","volume":"144","author":"Ragbourne","year":"2021","journal-title":"Acta Haematol"},{"key":"10.1016\/j.blre.2025.101360_bb0705","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fonc.2018.00103","article-title":"The relation of obesity-related hormonal and cytokine levels with multiple myeloma and non-Hodgkin lymphoma","volume":"8","author":"Hosgood","year":"2018","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.blre.2025.101360_bb0710","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/bloodadvances.2023010815","article-title":"Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups","volume":"8","author":"Shah","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101360_bb0715","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1182\/blood-2019-131906","article-title":"Polyunsaturated fatty acid (PUFA) signaling induces ferroptosis-mediated cell-death in multiple myeloma","volume":"134","author":"Panaroni","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2025.101360_bb0720","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb0725","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V92.3.802","article-title":"Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy","volume":"92","author":"Drach","year":"1998","journal-title":"Blood"},{"issue":"6810","key":"10.1016\/j.blre.2025.101360_bb0730","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.blre.2025.101360_bb0735","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jmcb\/mjy070","article-title":"Tumor suppressor p53 and metabolism","volume":"11","author":"Liu","year":"2019","journal-title":"J Mol Cell Biol"},{"issue":"12","key":"10.1016\/j.blre.2025.101360_bb0740","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.3390\/ijms17122074","article-title":"p53 as a regulator of lipid metabolism in cancer","volume":"17","author":"Parrales","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.blre.2025.101360_bb0745","article-title":"Inactivation of p53 drives breast cancer brain metastasis by altering fatty acid metabolism","volume":"2023","author":"Laue","year":"2023","journal-title":"bioRxiv"},{"issue":"7837","key":"10.1016\/j.blre.2025.101360_bb0750","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41586-020-2969-2","article-title":"A metastasis map of human cancer cell lines","volume":"588","author":"Jin","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.blre.2025.101360_bb0755","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00216-011-4882-x","article-title":"Distribution of lipids in human brain","volume":"401","author":"Veloso","year":"2011","journal-title":"Anal Bioanal Chem"},{"issue":"1","key":"10.1016\/j.blre.2025.101360_bb0760","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/jha2.72","article-title":"Marizomib: A novel therapeutic approach for the treatment of central nervous system myeloma","volume":"1","author":"Bazou","year":"2020","journal-title":"EJHaem"},{"issue":"7164","key":"10.1016\/j.blre.2025.101360_bb0765","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nature06244","article-title":"The human microbiome project","volume":"449","author":"Turnbaugh","year":"2007","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.blre.2025.101360_bb0770","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/106351501750435040","article-title":"Environmental diversity of bacteria and archaea","volume":"50","author":"DeLong","year":"2001","journal-title":"Syst Biol"},{"issue":"7285","key":"10.1016\/j.blre.2025.101360_bb0775","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature08821","article-title":"A human gut microbial gene catalogue established by metagenomic sequencing","volume":"464","author":"Qin","year":"2010","journal-title":"Nature"},{"issue":"7674","key":"10.1016\/j.blre.2025.101360_bb0780","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature23889","article-title":"Strains, functions and dynamics in the expanded human microbiome project","volume":"550","author":"Lloyd-Price","year":"2017","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.blre.2025.101360_bb0785","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41579-020-0367-2","article-title":"Host\u2013microbiota interactions in immune-mediated diseases","volume":"18","author":"Ruff","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.blre.2025.101360_bb0790","first-page":"361","article-title":"Role of the gut microbiota in nutrition and health","author":"Valdes","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.blre.2025.101360_bb0795","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40168-020-00854-5","article-title":"Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria","volume":"8","author":"Jian","year":"2020","journal-title":"Microbiome"},{"key":"10.1016\/j.blre.2025.101360_bb0800","doi-asserted-by":"crossref","first-page":"8269","DOI":"10.12659\/MSM.919988","article-title":"Fecal microbiota taxonomic shifts in Chinese multiple myeloma patients analyzed by quantitative polimerase chain reaction (QPCR) and 16S rRNA high-throughput sequencing","volume":"25","author":"Zhang","year":"2019","journal-title":"Med Sci Monit"},{"issue":"23","key":"10.1016\/j.blre.2025.101360_bb0805","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1158\/1078-0432.CCR-22-0723","article-title":"Sustained minimal residual disease negativity in multiple myeloma is associated with stool butyrate and healthier plant-based diets","volume":"28","author":"Shah","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.blre.2025.101360_bb0810","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1158\/1078-0432.CCR-23-0195","article-title":"Short-chain fatty acid production by gut microbiota predicts treatment response in multiple myeloma","volume":"30","author":"Rodr\u00edguez-Garc\u00eda","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.blre.2025.101360_bb0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmm.2020.151425","article-title":"Microbiota and cancer: host cellular mechanisms activated by gut microbial metabolites","volume":"310","author":"Tsvetikova","year":"2020","journal-title":"Int J Med Microbiol"},{"issue":"9","key":"10.1016\/j.blre.2025.101360_bb0820","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1194\/jlr.R036012","article-title":"The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism","volume":"54","author":"Den Besten","year":"2013","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.blre.2025.101360_bb0825","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/iub.573","article-title":"The monocarboxylate transporter family\u2014structure and functional characterization","volume":"64","author":"Halestrap","year":"2012","journal-title":"IUBMB Life"},{"issue":"21","key":"10.1016\/j.blre.2025.101360_bb0830","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1158\/0008-5472.CAN-16-2686","article-title":"MCT1 inhibitor AZD3965 increases mitochondrial metabolism, facilitating combination therapy and noninvasive magnetic resonance spectroscopy","volume":"77","author":"Beloueche-Babari","year":"2017","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.blre.2025.101360_bb0835","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00001574-199703000-00015","article-title":"Alternative fuels in the gastrointestinal tract","volume":"13","author":"Burrin","year":"1997","journal-title":"Curr Opin Gastroenterol"},{"issue":"6","key":"10.1016\/j.blre.2025.101360_bb0840","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1073\/pnas.1322269111","article-title":"The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition","volume":"111","author":"Chang","year":"2014","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb0845","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1136\/gut.47.3.397","article-title":"Butyrate inhibits inflammatory responses through NF\u03baB inhibition: implications for Crohn\u2019s disease","volume":"47","author":"Segain","year":"2000","journal-title":"Gut"},{"issue":"7480","key":"10.1016\/j.blre.2025.101360_bb0850","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature12726","article-title":"Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation","volume":"504","author":"Arpaia","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.blre.2025.101360_bb0855","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/s41598-018-36941-9","article-title":"Prominent action of butyrate over \u03b2-hydroxybutyrate as histone deacetylase inhibitor, transcriptional modulator and anti-inflammatory molecule","volume":"9","author":"Chriett","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2025.101360_bb0860","first-page":"226","article-title":"Dietary inhibitors of histone deacetylases in intestinal immunity and homeostasis","volume":"4","author":"Schilderink","year":"2013","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.blre.2025.101360_bb0865","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.molcel.2012.08.033","article-title":"The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation","volume":"48","author":"Donohoe","year":"2012","journal-title":"Mol Cell"},{"issue":"6145","key":"10.1016\/j.blre.2025.101360_bb0870","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1126\/science.1241165","article-title":"The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis","volume":"341","author":"Smith","year":"2013","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.blre.2025.101360_bb0875","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.immuni.2018.10.013","article-title":"The microbial metabolite butyrate stimulates bone formation via T regulatory cell-mediated regulation of WNT10B expression","volume":"49","author":"Tyagi","year":"2018","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.blre.2025.101360_bb0880","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1038\/s41467-018-07305-8","article-title":"Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression","volume":"9","author":"Calcinotto","year":"2018","journal-title":"Nat Commun"},{"issue":"165","key":"10.1016\/j.blre.2025.101360_bb0885","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.sger.2023.12.003","article-title":"The kidney, its anatomy and main functions","volume":"29","author":"Levassort","year":"2024","journal-title":"Soins Gerontol"},{"issue":"15","key":"10.1016\/j.blre.2025.101360_bb0890","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1182\/bloodadvances.2019031914","article-title":"Pathophysiology and management of monoclonal gammopathy of renal significance","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv"},{"issue":"26","key":"10.1016\/j.blre.2025.101360_bb0895","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb0900","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1128\/jb.96.3.617-622.1968","article-title":"Degradation of uric acid by certain aerobic bacteria","volume":"96","author":"Rouf","year":"1968","journal-title":"J Bacteriol"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb0905","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02760-21","article-title":"In Streptococcus thermophilus, ammonia from urea hydrolysis paradoxically boosts acidification and reveals a new regulatory mechanism of glycolysis","volume":"10","author":"Arioli","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"5","key":"10.1016\/j.blre.2025.101360_bb0910","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.3390\/curroncol29050243","article-title":"The chemo-gut pilot study: associations between gut microbiota, gastrointestinal symptoms, and psychosocial health outcomes in a cross-sectional sample of young adult cancer survivors","volume":"29","author":"Deleemans","year":"2022","journal-title":"Curr Oncol"},{"issue":"10","key":"10.1016\/j.blre.2025.101360_bb0915","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.3390\/ijms21103688","article-title":"Gut microbiota metabolism and interaction with food components","volume":"21","author":"Vernocchi","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.blre.2025.101360_bb0920","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.metabol.2012.01.017","article-title":"The health benefits of dietary fiber: beyond the usual suspects of type 2 diabetes mellitus, cardiovascular disease and colon cancer","volume":"61","author":"Kaczmarczyk","year":"2012","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.blre.2025.101360_bb0925","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1462-2920.2007.01281.x","article-title":"Interactions and competition within the microbial community of the human colon: links between diet and health","volume":"9","author":"Flint","year":"2007","journal-title":"Environ Microbiol"},{"key":"10.1016\/j.blre.2025.101360_bb0930","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fmicb.2016.00185","article-title":"Intestinal short chain fatty acids and their link with diet and human health","volume":"7","author":"R\u00edos-Covi\u00e1n","year":"2016","journal-title":"Front Microbiol"},{"issue":"14","key":"10.1016\/j.blre.2025.101360_bb0935","doi-asserted-by":"crossref","first-page":"5859","DOI":"10.1073\/pnas.0901529106","article-title":"Characterizing a model human gut microbiota composed of members of its two dominant bacterial phyla","volume":"106","author":"Mahowald","year":"2009","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"10.1016\/j.blre.2025.101360_bb0940","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jfda.2016.09.006","article-title":"Classification and regulatory perspectives of dietary fiber","volume":"25","author":"Dai","year":"2017","journal-title":"J Food Drug Anal"},{"issue":"2","key":"10.1016\/j.blre.2025.101360_bb0945","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.foodchem.2005.04.040","article-title":"By-products from different citrus processes as a source of customized functional fibres","volume":"100","author":"Mar\u00edn","year":"2007","journal-title":"Food Chem"},{"key":"10.1016\/j.blre.2025.101360_bb0950","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2180-10-13","article-title":"Effects of apples and specific apple components on the cecal environment of conventional rats: role of apple pectin","volume":"10","author":"Licht","year":"2010","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.blre.2025.101360_bb0955","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.3389\/fmicb.2018.02976","article-title":"Bacteroides fragilis prevents Clostridium difficile infection in a mouse model by restoring gut barrier and microbiome regulation","volume":"9","author":"Deng","year":"2018","journal-title":"Front Microbiol"},{"issue":"134\u201342","key":"10.1016\/j.blre.2025.101360_bb0960","article-title":"Fenugreek galactomannan and citrus pectin improve several parameters associated with glucose metabolism and modulate gut microbiota in mice","volume":"46","author":"Shtriker","year":"2018","journal-title":"Nutrition"},{"issue":"11","key":"10.1016\/j.blre.2025.101360_bb0965","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206047","article-title":"Dietary intake is associated with risk of multiple myeloma and its precursor disease","volume":"13","author":"Thordardottir","year":"2018","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb0970","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/bloodadvances.2023011608","article-title":"Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse population","volume":"8","author":"Joseph","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb0975","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1079\/PHN2002430","article-title":"EPIC\u2013Oxford: lifestyle characteristics and nutrient intakes in a cohort of 33 883 meat-eaters and 31 546 non meat-eaters in the UK","volume":"6","author":"Davey","year":"2003","journal-title":"Public Health Nutr"},{"key":"10.1016\/j.blre.2025.101360_bb0980","doi-asserted-by":"crossref","first-page":"378S","DOI":"10.3945\/ajcn.113.071266","article-title":"Cancer in British vegetarians: updated analyses of 4998 incident cancers in a cohort of 32,491 meat eaters, 8612 fish eaters, 18,298 vegetarians, and 2246 vegans","volume":"100","author":"Key","year":"2014","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"10.1016\/j.blre.2025.101360_bb0985","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1017\/S0029665121003748","article-title":"Plant-based diets and long-term health: findings from the EPIC-Oxford study","volume":"81","author":"Key","year":"2022","journal-title":"Proc Nutr Soc"},{"issue":"2","key":"10.1016\/j.blre.2025.101360_bb0990","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41375-023-02132-3","article-title":"Pre-diagnosis dietary patterns and risk of multiple myeloma in the NIH-AARP diet and health study","volume":"38","author":"Castro","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101360_bb0995","article-title":"A high-fiber plant-based diet in myeloma precursor disorders \u2013 results from the NUTRIVENTION clinical trial and preclinical Vk*MYC Model","author":"Shah","year":"2025","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.blre.2025.101360_bb1000","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1123\/ijsnem.22.6.452","article-title":"Effect of intake of different dietary protein sources on plasma amino acid profiles at rest and after exercise","volume":"22","author":"Burke","year":"2012","journal-title":"Int J Sport Nutrit Exerc Metab"},{"key":"10.1016\/j.blre.2025.101360_bb1005","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood-2024-202224","article-title":"A high-fiber dietary intervention (NUTRIVENTION) in precursor plasma cell disorders improves biomarkers of disease and may delay progression to myeloma","volume":"144","author":"Shah","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101360_bb1010","series-title":"Maple Syrup Urine Disease: Branched-Chain Keto-Aciduria","author":"Dancis","year":"1960"},{"issue":"1","key":"10.1016\/j.blre.2025.101360_bb1015","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11060-020-03417-8","article-title":"Ketogenic diets as an adjuvant therapy for glioblastoma (KEATING): a randomized, mixed methods, feasibility study","volume":"147","author":"Martin-McGill","year":"2020","journal-title":"J Neuro-Oncol"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb1020","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27561","article-title":"Ketogenic diet treatment in recurrent diffuse intrinsic pontine glioma in children: a safety and feasibility study","volume":"66","author":"van der Louw","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.blre.2025.101360_bb1025","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1667\/RR14668.1","article-title":"Consuming a ketogenic diet while receiving radiation and chemotherapy for locally advanced lung cancer and pancreatic cancer: the University of Iowa experience of two phase 1 clinical trials","volume":"187","author":"Zahra","year":"2017","journal-title":"Radiat Res"},{"issue":"5","key":"10.1016\/j.blre.2025.101360_bb1030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036197","article-title":"The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma","volume":"7","author":"Abdelwahab","year":"2012","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.blre.2025.101360_bb1035","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.cmet.2018.12.020","article-title":"Loss of BCAA catabolism during carcinogenesis enhances mTORC1 activity and promotes tumor development and progression","volume":"29","author":"Ericksen","year":"2019","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.blre.2025.101360_bb1040","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41556-019-0455-6","article-title":"BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma","volume":"22","author":"Li","year":"2020","journal-title":"Nat Cell Biol"},{"issue":"5","key":"10.1016\/j.blre.2025.101360_bb1045","doi-asserted-by":"crossref","DOI":"10.3390\/nu13051388","article-title":"Efficacy of low-carbohydrate ketogenic diet as an adjuvant cancer therapy: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Yang","year":"2021","journal-title":"Nutrients"},{"issue":"25","key":"10.1016\/j.blre.2025.101360_bb1050","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1200\/JCO.2016.72.0326","article-title":"Low-fat dietary pattern and breast cancer mortality in the Women\u2019s Health Initiative randomized controlled trial","volume":"35","author":"Chlebowski","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2025.101360_bb1055","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41591-020-01209-1","article-title":"Effect of a plant-based, low-fat diet versus an animal-based, ketogenic diet on ad libitum energy intake","volume":"27","author":"Hall","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2025.101360_bb1060","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00277-017-3016-8","article-title":"Vitamin D and plasma cell dyscrasias: reviewing the significance","volume":"96","author":"Burwick","year":"2017","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.blre.2025.101360_bb1065","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/bloodadvances.2019001411","article-title":"Vitamin D deficiency predicts for poor overall survival in white but not African American patients with multiple myeloma","volume":"4","author":"Yellapragada","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb1070","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.3390\/curroncol30030248","article-title":"Vitamin D and multiple myeloma: a scoping review","volume":"30","author":"Mirhosseini","year":"2023","journal-title":"Curr Oncol"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb1075","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.1365-2141.2000.02046.x","article-title":"Induction of apoptosis by vitamin D3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase","volume":"109","author":"Park","year":"2000","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2025.101360_bb1080","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1006\/excr.1999.4735","article-title":"Cell cycle arrest induced by the vitamin D3 analog EB1089 in NCI-H929 myeloma cells is associated with induction of the cyclin-dependent kinase inhibitor p27","volume":"254","author":"Park","year":"2000","journal-title":"Exp Cell Res"},{"issue":"8","key":"10.1016\/j.blre.2025.101360_bb1085","doi-asserted-by":"crossref","DOI":"10.3390\/cells10082007","article-title":"The interdependency and co-regulation of the vitamin d and cholesterol metabolism","volume":"10","author":"Warren","year":"2021","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb1090","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4103\/1947-2714.153919","article-title":"Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin D supplementation","volume":"7","author":"Khayznikov","year":"2015","journal-title":"N Am J Med Sci"},{"key":"10.1016\/j.blre.2025.101360_bb1095","first-page":"56","article-title":"Impact of vitamin D status on statin-induced myopathy","volume":"6","author":"Riche","year":"2016","journal-title":"J Clin Transl Endocrinol"},{"issue":"1","key":"10.1016\/j.blre.2025.101360_bb1100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.atherosclerosis.2010.11.039","article-title":"The relationship of vitamin D deficiency to statin myopathy","volume":"215","author":"Gupta","year":"2011","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.blre.2025.101360_bb1105","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.3390\/nu11122888","article-title":"Effect of vitamin D supplementation on faecal microbiota: a randomised clinical trial","volume":"11","author":"Naderpoor","year":"2019","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.blre.2025.101360_bb1110","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2353\/ajpath.2010.090998","article-title":"Vitamin D receptor negatively regulates bacterial-stimulated NF-\u03baB activity in intestine","volume":"177","author":"Wu","year":"2010","journal-title":"Am J Pathol"},{"issue":"7","key":"10.1016\/j.blre.2025.101360_bb1115","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/mnfr.201300928","article-title":"Low vitamin D status throughout life results in an inflammatory prone status but does not alter bone mineral or strength in healthy 3-month-old CD-1 male mice","volume":"58","author":"Jahani","year":"2014","journal-title":"Mol Nutr Food Res"},{"issue":"5","key":"10.1016\/j.blre.2025.101360_bb1120","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s13402-018-0385-5","article-title":"Targeting glucose transport and the NAD pathway in tumor cells with STF-31: a re-evaluation","volume":"41","author":"Kraus","year":"2018","journal-title":"Cell Oncol"},{"key":"10.1016\/j.blre.2025.101360_bb1125","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.leukres.2015.12.008","article-title":"Inhibition of glucose transporter 1 induces apoptosis and sensitizes multiple myeloma cells to conventional chemotherapeutic agents","volume":"41","author":"Matsumoto","year":"2016","journal-title":"Leuk Res"},{"issue":"94","key":"10.1016\/j.blre.2025.101360_bb1130","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002394","article-title":"Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality","volume":"3","author":"Chan","year":"2011","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.blre.2025.101360_bb1135","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/CAD.0000000000000094","article-title":"Killing multiple myeloma cells with the small molecule 3-bromopyruvate: implications for therapy","volume":"25","author":"Majkowska-Skrobek","year":"2014","journal-title":"Anti-Cancer Drugs"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb1140","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1039\/C4SC01963F","article-title":"The energy blocker inside the power house: Mitochondria targeted delivery of 3-bromopyruvate","volume":"6","author":"Marrache","year":"2015","journal-title":"Chem Sci"},{"issue":"21","key":"10.1016\/j.blre.2025.101360_bb1145","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1182\/blood.V122.21.1921.1921","article-title":"Combination Of 2-Deoxy-D-glucose with ABT-199 efficiently kills all molecular subgroups of myeloma cells","volume":"122","author":"Halliez","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2025.101360_bb1150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167323","article-title":"Mitochondrial-targeted decyl-triphenylphosphonium enhances 2-deoxy-D-glucose mediated oxidative stress and clonogenic killing of multiple myeloma cells","volume":"11","author":"Schibler","year":"2016","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/j.blre.2025.101360_bb1155","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1182\/blood.V122.21.3172.3172","article-title":"A small molecule, shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells","volume":"122","author":"Wada","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101360_bb1160","article-title":"Shikonin induces ferroptosis in multiple myeloma via GOT1-mediated ferritinophagy","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb1165","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3892\/ijo.2014.2804","article-title":"Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells","volume":"46","author":"Wada","year":"2015","journal-title":"Int J Oncol"},{"key":"10.1016\/j.blre.2025.101360_bb1170","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1182\/blood-2023-180268","article-title":"Inhibiting FOXM1 sensitizes myeloma cells to BCL2 inhibitor venetoclax by repressing MYC pathway","volume":"142","author":"Zhou","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101360_bb1175","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202508822","article-title":"Inhibition of FOXM1 synergizes with BH3 mimetics venetoclax and sonrotoclax in killing multiple myeloma cells through repressing MYC pathway","author":"Wen","year":"2025","journal-title":"Adv Sci"},{"issue":"1","key":"10.1016\/j.blre.2025.101360_bb1180","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1186\/s12967-024-05452-9","article-title":"Synergistic effect of FOXM1 and BCL-2 inhibition in a preclinical treatment study on multiple myeloma","volume":"22","author":"Zhou","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.blre.2025.101360_bb1185","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.canlet.2021.02.020","article-title":"Inhibition of the \u029f-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors","volume":"507","author":"Prelowska","year":"2021","journal-title":"Cancer Lett"},{"issue":"3","key":"10.1016\/j.blre.2025.101360_bb1190","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11523-024-01054-z","article-title":"ASCT2-targeting antibody-drug conjugate MEDI7247 in adult patients with relapsed\/refractory hematological malignancies: a first-in-human, Phase 1 study","volume":"19","author":"Maris","year":"2024","journal-title":"Target Oncol"},{"key":"10.1016\/j.blre.2025.101360_bb1195","series-title":"Discovery and Development of MEDI7247, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate Targeting ASCT2, for Treating Hematological Cancers","author":"Pore","year":"2018"},{"issue":"8_Supplement_1","key":"10.1016\/j.blre.2025.101360_bb1200","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1158\/1538-7445.AM2025-1580","article-title":"HuB14-VA-PL2202, a novel antibody-drug conjugate targeting ASCT2, a novel ADC target over-ex-pressed in both solid and hematological cancers","volume":"85","author":"Cucchi","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2025.101360_bb1205","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood-2019-125970","article-title":"Interim analysis of a phase II study of the glutaminase inhibitor telaglenastat (CB-839) in combination with azacitidine in advanced myelodysplastic syndrome (MDS)","volume":"134","author":"Guerra","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101360_bb1210","series-title":"A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination With Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma","author":"Gonsalves","year":"2022"},{"issue":"22","key":"10.1016\/j.blre.2025.101360_bb1215","doi-asserted-by":"crossref","first-page":"5672","DOI":"10.1182\/blood.V128.22.5672.5672","article-title":"EZH2 inhibitors are broadly efficacious in multiple myeloma as single agent and in combination with standard of care therapeutics","volume":"128","author":"Arora","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2025.101360_bb1220","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12032-023-02025-6","article-title":"The roles of EZH2 in cancer and its inhibitors","volume":"40","author":"Liu","year":"2023","journal-title":"Med Oncol"},{"key":"10.1016\/j.blre.2025.101360_bb1225","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2024-198403","article-title":"Mezigdomide (MEZI) in novel-novel combinations for relapsed or refractory multiple myeloma (RRMM): preliminary results from the CA057-003 trial","volume":"144","author":"Costa","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2025.101360_bb1230","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00280-024-04658-4","article-title":"Pharmacology and pharmacokinetics of tazemetostat","volume":"93","author":"Orleni","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.blre.2025.101360_bb1235","series-title":"Patients With Relapsed or Refractory B-Cell Non-Hodgkin lymphoma (NHL)","article-title":"Phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2)","author":"Morschhauser","year":"2016"},{"key":"10.1016\/j.blre.2025.101360_bb1240","series-title":"Inhibition of Fatty Acid Metabolism Reduces Human Myeloma Cells Proliferation","author":"Tirado-V\u00e9lez","year":"2012"},{"issue":"8","key":"10.1016\/j.blre.2025.101360_bb1245","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nsmb1265","article-title":"Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat","volume":"14","author":"Pemble","year":"2007","journal-title":"Nat Struct Mol Biol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101360_bb1250","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/blood-2022-166444","article-title":"Multiomics analysis of IMiD\/CELMoD resistant multiple myeloma models uncovers novel and targetable vulnerabilities in the srebp lipid synthesis pathway","volume":"140","author":"Bird","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101360_bb1255","first-page":"1","article-title":"Lipin1-dependent transcriptional inactivation of SREBPs contributes to selinexor sensitivity in multiple myeloma","author":"Wang","year":"2025","journal-title":"Acta Pharmacol Sin"},{"issue":"8","key":"10.1016\/j.blre.2025.101360_bb1260","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2017-08-797886","article-title":"Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2025.101360_bb1265","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/path.6066","article-title":"Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis","volume":"260","author":"Van der Vreken","year":"2023","journal-title":"J Pathol"},{"key":"10.1016\/j.blre.2025.101360_bb1270","article-title":"Pyruvate from bone marrow mesenchymal stem cells supports myeloma redox homeostasis and anabolism","volume":"2024","author":"Vera-Sig\u00fcenza","year":"2024","journal-title":"bioRxiv"},{"issue":"8","key":"10.1016\/j.blre.2025.101360_bb1275","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-22-2263","article-title":"A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer","volume":"29","author":"Halford","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.blre.2025.101360_bb1280","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40164-024-00507-5","article-title":"Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives","volume":"13","author":"Pu","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.blre.2025.101360_bb1285","series-title":"HDAC3 Maintains DNMT1 Through Dual Mechanisms in Multiple Myeloma","author":"Harada","year":"2016"},{"issue":"10","key":"10.1016\/j.blre.2025.101360_bb1290","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2018.189969","article-title":"Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I\/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)","volume":"103","author":"Waldschmidt","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.blre.2025.101360_bb1295","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.1","article-title":"Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"4","author":"Siegel","year":"2014","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.blre.2025.101360_bb1300","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/cncr.25584","article-title":"Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma","volume":"117","author":"Niesvizky","year":"2011","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.blre.2025.101360_bb1305","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.1182\/blood-2011-03-339879","article-title":"A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma","volume":"118","author":"Harrison","year":"2011","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25001055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25001055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:11:11Z","timestamp":1788221471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25001055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":261,"alternative-id":["S0268960X25001055"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101360","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic alterations in multiple myeloma and extramedullary disease- a novel niche of therapeutic targets","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101360","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101360"}}